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BIS-QUATERNARY AMMONIUM SALTS AND 
METHODS FOR MODULATING NEURONAL 
NICOTINIC ACETYLCHOLINE RECEPTORS 
CONTINUING APPLICATION DATA 
This application claims bene?t of US. Provisional Appli 
cation No. 60/8 1 4,640, ?led Jun. 16, 2006, Which is incorpo 
rated herein by reference in its entirety. 
IDENTIFICATION OF FEDERAL FUNDING 
The present invention Was supported by Grant NIH 
Ul9DA0l7548 from the National Institutes of Health, and 
therefore the government may have rights in the invention. 
FIELD OF THE INVENTION 
The invention relates to bis-quatemary ammonium salts 
and their use in modulating nicotinic acetylcholine receptors. 
BACKGROUND OF THE INVENTION 
S-Nicotine (NIC) activates presynaptic and postsynaptic 
neuronal nicotinic receptors that evoke the release of neu 
rotransmitters from presynaptic terminals and that modulate 
the depolariZation state of the postsynaptic neuronal mem 
brane, respectively. Thus, S-nicotine produces its effect by 
binding to a family of ligand-gated ion channels, stimulated 
by acetylcholine (ACh) or S-nicotine Which causes the ion 
channel to open and cations to ?ux With a resulting rapid 
(millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of tWo types of 
subunits, 0t and [3, and assemble as heteromeric receptors With 
the general stoichiometry of 2a and 3[3 or as homomeric 
receptors With 5a subunits. Nine subtypes of the ot subunit 
(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are 
found in the central nervous system. The mo st common nico 
tinic receptor subtype in the brain is composed of tWo (X4 and 
three [32 subunits, i.e., (X462. These subunits display different, 
but overlapping, patterns of expression in the brain. Examples 
of heteromeric receptor subtypes include (X462, (X362, (X3 [34, 
(X662, (x6[32[33, (x40t5[32, (x60t5[32, (x60t4[32, (x60t4[32[33, 
(x4[32[34, 3[32[34, and others. The predominant homomeric 
subtype includes (x7, but other combinations have also been 
proposed. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combina 
tions of assemblies of subunits into functional receptor pro 
teins, Which affords a Wide diversity of pharmacological 
speci?city. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3H]ACh. It has 
been estimated that over 90% of [3H]NIC binding in the brain 
is due to association With the heteromeric receptor that is 
composed of (X4 and [32 subunits. Also abundant in the central 
nervous system are the homomeric receptors labeled by [3 H] 
methyllycaconitine (MLA), Which has high af?nity for the (X7 
nicotinic receptor subtype. Nicotinic receptor subtypes can 
be studied using functional assays, such as NIC-evoked neu 
rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H] 
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norepinephrine (NE) release, [3H]serotonin (5-HT) release, 
[3H]gamma-aminobutyric acid (GABA) release and [3H] 
glutamate release) from superfused rat brain slices. Nicotinic 
receptors are located in the cell body and terminal areas of 
these neurotransmitter systems. NIC facilitates neurotrans 
mitter release from nerve terminals. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of inter 
est in developing novel, subtype-selective agonists and/or 
antagonists. Some of these agonists are currently being evalu 
ated in clinical trials for cognitive enhancement and neuro 
protective effects, potentially bene?cial for disease states 
such as AlZheimer’s and Parkinson’s disease, as Well for 
treatment of drug abuse, depression, obesity and pain relief. 
SUMMARY OF INVENTION 
In one embodiment, compounds corresponding to the fol 
loWing structure are provided. 
XZQG-DRIiHZC-LIQ-LZ-CHZiRZG-DQXI (I) 
XIQ and X2© are each independently an organic or inor 
ganic anion. 
Q is selected from phenylene, biphenylene, 4CH:CHi, 
4CH:CH4CH:CHi, iCECi, 4CECiCECi, 
4Oi(CH2)24Oi, and 4Oi(CH2)24Oi(CH2)2i 
0*. 
L1 and L2 are each independently selected from alkyl, sub 
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi 
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi 
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky 
nyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic; SOYl, SOZYI, SOZOYl or SO2NHYl, WhereYl 
is selected from hydrogen, loWer alkyl, alkenyl, alkynyl or 
aryl, and where Y1 is not hydrogen in SOYl and if Y1 is 
alkenyl or alkynyl, the site of unsaturation is not conjugated 
With a heteroatom; COY2, Where Y2 is selected from hydro 
gen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub 
stituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, sub 
stituted alkylaryl, arylalkyl, substituted arylalkyl, arylalk 
enyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, or substituted heterocyclic, and 
Where if Y2 comprises alkenyl or alkynyl, the site of unsat 
uration is not conjugated With the carbonyl group; 0Y3, 
Where Y3 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky 
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or 
substituted heterocyclic, Where if Y3 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
oxygen; NY4Y5, Where Y4 and Y5 are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted 
heterocyclic, Where if Y4 orY5 comprises alkenyl or alkynyl, 
the site of unsaturation is not conjugated With the nitrogen; 
SY6, Where Y6 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
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lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, or substituted heterocyclic, 
and Where if Y6 comprises alkenyl or alkynyl, the site of 
unsaturation is not conjugated With the sulfur. 
R1 and R2 are each independently ?ve or six membered 
nitrogen containing rings as shoWn in formulas (HA) and 
(IIB). 
(HA) 
(11B) 
Al is carbon, nitrogen, sulfur or oxygen, provided that 
WhenAl is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R3 is absent, and When A1 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R3 and R4 are absent. 
A2 is carbon, nitrogen, sulfur or oxygen, provided that 
When A2 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R5 is absent, and When A2 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R5 and R6 are absent. 
A3 is carbon, nitrogen, sulfur or oxygen, provided that 
When A3 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R7 is absent, and When A3 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R7 and R8 are absent. 
A4 is carbon, nitrogen, sulfur or oxygen, provided that 
When A4 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R9 is absent, and When A4 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R9 and R10 are absent. 
A5 is carbon, nitrogen, sulfur or oxygen, provided that 
When A5 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R11 is absent, and When A5 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R1 1 and R12 are absent. 
A6 is carbon, nitrogen, sulfur or oxygen, provided that 
When A6 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R14 is absent, and When A6 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R14 and R15 are absent. 
A7 is carbon, nitrogen, sulfur or oxygen, provided that 
When A7 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R16 is absent, and When A7 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R16 and R17 are absent. 
A8 is carbon, nitrogen, sulfur or oxygen, provided that 
When A8 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R18 is absent, and When A8 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R18 and R19 are absent. 
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A9 is carbon, nitrogen, sulfur or oxygen, provided that 
When A9 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R20 is absent, and When A9 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R20 and R21 are absent. 
R13 or R22 is absent When any of the bonds to the ammo 
nium nitrogen is unsaturated, and R13 or R22 is a straight chain 
or branched alkyl group of four carbons or feWer When all of 
the bonds to the ammonium nitrogen are saturated. 
R3 R4’ R5 R6’ R7’ R8’ R9’ R10’ R11’ aHdRIZ OrRl4’ R15’ R16’ 
R17, R18, R19, R20, and R21, When present, are each indepen 
dently selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky 
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, substituted heterocyclic, halo, 
cyano, nitro, or R4 and R5 together With A1 and A2, or R5 and 
R7 together With A2 and A3, or R15 and R16 together With A6 
and A7, or R1 6 and R1 8 together WithA7 andA8 independently 
form a three to eight member cyclolkane, substituted cycloal 
kane, cycloalkene, substituted cycloalkene, aryl, substituted 
aryl, heterocycle With one to three hetero atoms of nitrogen, 
oxygen or sulfur in the ring, or substituted heterocycle With 
one to three hetero atoms of nitrogen, oxygen or sulfur in the 
ring; and When all of the bonds to the ring ammonium nitro 
gen are saturated, then any ofR3, R4, R5, R6, R7, R8, R9, R10, 
R11’ R12’ R13’ R14’ R15’ R16’ R17’ R18’ R19’ R20’ R21 or R22 
Which is attached to the ammonium nitrogen is a straight or 
branched alkyl group of four carbons or feWer. 
In another embodiment, a composition is provided com 
prising a pharmaceutically acceptable carrier and a com 
pound as described above. 
In another embodiment, a method is provided for selec 
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating a central nervous system associated disor 
der, for example, schizophrenia, Tourettes’, Huntington’s 
Chorea, Parkinson’s disease, AlZheimer’s disease, and 
related conditions, comprising administering a therapeuti 
cally effective amount of a compound as described above to a 
mammalian subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/or treating substance use and/or abuse comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating gastrointestinal tract disorders comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
Other methods, features and advantages of the present 
invention Will be or become apparent to one With skill in the 
art upon examination of the folloWing detailed descriptions. It 
is intended that all such additional methods, features and 
advantages be included Within this description, be Within the 
scope of the present invention, and be protected by the accom 
panying claims. 
DETAILED DESCRIPTION OF INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
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limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 
is in no Way intended to limit the scope of the present inven 
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms “a,” “an,” and “the” include plural 
references unless the context clearly dictates otherWise. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meanings as commonly under 
stood by one of ordinary skill in the art to Which this invention 
belongs. All publications cited herein are incorporated herein 
by reference in their entirety for the purpose of describing and 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection With the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 
The term “nicotinic acetylcholine receptor” refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine Which also bind to S-nicotine. The term “nico 
tinic acetylcholine receptor” includes the term “neuronal 
nicotinic acetylcholine receptor.” 
The terms “subtype of nicotinic acetylcholine receptor,” 
and “nicotinic acetylcholine receptor subtype” refer to vari 
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or hetero 
meric complex, or multiple homomeric or heteromeric com 
plexes. 
The term “agonist” refers to a substance Which interacts 
With a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term “partial agonist” refers to a substance Which 
interacts With and activates a receptor to a lesser degree than 
an agonist. 
The term “antagonist” refers to a substance Which interacts 
With and decreases the extent or duration of a physiological 
response of that receptor. 
The terms “disorder,” “disease,” and “condition” are used 
inclusively and refer to any status deviating from normal. 
The term “central nervous system associated disorders” 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated With the alteration of normal 
neurotransmitter release in the brain. 
The term “loWer alkyl” refers to straight or branched chain 
alkyl radicals having in the range of l to 4 carbon atoms. 
The term “alkyl” refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and “substituted alkyl” 
refers to alkyl radicals further bearing one or more substitu 
ents including, but not limited to, hydroxy, alkoxy (of a loWer 
alkyl group), mercapto (of a loWer alkyl group), aryl, hetero 
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car 
boxyl, carbarnate, sulfonyl, and sulfonamide. 
The term “cycloalkyl” refers to cyclic ring-containing moi 
eties containing 3 to 8 carbon atoms, and “substituted 
cycloalkyl” refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term “alkenyl” refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon double 
bond and having 2 to 19 carbon atoms, and “substituted 
alkenyl” refers to alkenyl groups further bearing-one or more 
substituents as set forth above. 
The term “alkynyl” refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon triple 
bond and having 2 to 19 carbon atoms, and “substituted 
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alkynyl” refers to alkynyl moieties further bearing one or 
more substituents as set forth above. 
The term “aryl” refers to aromatic groups having 6 to 24 
carbon atoms, and “substituted aryl” refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term “alkylaryl” refers to alkyl-substituted aryl 
groups, and “substituted alkylaryl” refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkyl” refers to aryl-substituted alkyl 
groups, and “substituted arylalkyl” refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkenyl” refers to aryl-substituted alkenyl 
groups, and “substituted arylalkenyl” refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term “arylalkynyl” refers to aryl-substituted alkynyl 
groups, and “substituted arylalkynyl” refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term “heterocyclic” refers to cyclic moieties contain 
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and “substituted heterocyclic” 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term “acyl” refers to alkyl-carbonyl groups, and “sub 
stituted acyl” refers to acyl groups further bearing one or 
more substituents as set forth above. 
The term “halogen” refers to ?uoride, chloride, bromide or 
iodide groups. 
It is understood that in all substituted groups de?ned above, 
polymers arrived at by de?ning sub stituents With further sub 
stituents to themselves (e. g. substituted aryl having a substi 
tuted aryl group as a substituent Which is itself substituted 
With a substituted aryl group, etc.) are not intended for inclu 
sion herein. In such cases, the maximum number of such 
substituents is three. That is to say that each of the above 
de?nitions is constrained by a limitation that, for example, 
substituted aryl groups are limited to -substituted aryl-(sub 
stituted aryl)-sub stituted aryl. 
Compounds of the present invention are bis-quaternary 
ammonium salts corresponding to Formula (I): 
XIQ and X2© are each independently an organic or inor 
ganic anion. 
Q is selected from phenylene, biphenylene, 4CH:CHi, 
4CH:CH4CH:CHi, iCECi, 4CECiCECi, 
4Oi(CH2)24Oi, and 4OiCH2)2iO(CH2)24Oi. 
L1 and L2 are each independently selected from alkyl, sub 
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi 
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi 
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky 
nyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic; SOYl, SOZYI, SOZOYl or SO2NHYl, WhereYl 
is selected from hydrogen, loWer alkyl, alkenyl, alkynyl or 
aryl, and where Y1 is not hydrogen in SOYl and if Y1 is 
alkenyl or alkynyl, the site of unsaturation is not conjugated 
With a heteroatom; COY2, Where Y2 is selected from hydro 
gen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub 
stituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, sub 
stituted alkylaryl, arylalkyl, substituted arylalkyl, arylalk 
enyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, or substituted heterocyclic, and 
Where if Y2 comprises alkenyl or alkynyl, the site of unsat 
uration is not conjugated With the carbonyl group; 0Y3, 
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Where Y3 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky 
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or 
substituted heterocyclic, Where if Y3 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
oxygen; NY4Y5, Where Y4 and Y5 are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted 
heterocyclic, Where if Y4 orY5 comprises alkenyl or alkynyl, 
the site of unsaturation is not conjugated With the nitrogen; 
SY6, Where Y6 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, or substituted heterocyclic, 
and Where if Y6 comprises alkenyl or alkynyl, the site of 
unsaturation is not conjugated With the sulfur. 
R1 and R2 are each independently ?ve or six membered 
nitrogen containing rings as shoWn in formulas (HA) and 
(HB). 
Al is carbon, nitrogen, sulfur or oxygen, provided that 
WhenAl is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R3 is absent, and When A1 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R3 and R4 are absent. 
A2 is carbon, nitrogen, sulfur or oxygen, provided that 
When A2 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R5 is absent, and When A2 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R5 and R6 are absent. 
A3 is carbon, nitrogen, sulfur or oxygen, provided that 
When A3 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R7 is absent, and When A3 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R7 and R8 are absent. 
A4 is carbon, nitrogen, sulfur or oxygen, provided that 
When A4 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R9 is absent, and When A4 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R9 and R10 are absent. 
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A5 is carbon, nitrogen, sulfur or oxygen, provided that 
When A5 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R11 is absent, and When A5 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R11 and R12 are absent. 
A6 is carbon, nitrogen, sulfur or oxygen, provided that 
When A6 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R14 is absent, and When A6 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R14 and R15 are absent. 
A7 is carbon, nitrogen, sulfur or oxygen, provided that 
When A7is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R16 is absent, and When A7 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R16 and R17 are absent. 
A8 is carbon, nitrogen, sulfur or oxygen, provided that 
When A8 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R18 is absent, and When A8 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R18 and R19 are absent. 
A9 is carbon, nitrogen, sulfur or oxygen, provided that 
When A9 is a carbon and joins a ring atom With an unsaturated 
bond or is a nitrogen, R20 is absent, and When A9 is sulfur or 
oxygen or joins a ring atom With an unsaturated bond and is a 
nitrogen, both R20 and R21 are absent. 
R13 or R22 is absent When any of the bonds to the ammo 
nium nitrogen is unsaturated, and R13 or R22 is a straight chain 
or branched alkyl group of four carbons or feWer When all of 
the bonds to the ammonium nitrogen are saturated. 
R3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ and R12’ or R14’ R15’ 
R16, R17, R18, R19, R20, and R21, When present, are each 
independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, or R4 and R5 together WithAl and A2, or R5 
and R7 together With A2 and A3 , or R15 and R16 together With 
A6 and A7, or R16 and R18 together With A7 and A8 indepen 
dently form a three to eight member cyclolkane, substituted 
cycloalkane, cycloalkene, substituted cycloalkene, aryl, sub 
stituted aryl, heterocycle With one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring, or substituted hetero 
cycle With one to three hetero atoms of nitrogen, oxygen or 
sulfur in the ring; and When all of the bonds to the ring 
ammonium nitrogen are saturated, then any of R3 , R4, R5 , R6, 
R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16, R17’ R18, R19’ 
R20, R21 or R22 Which is attached to the ammonium nitrogen 
is a straight or branched alkyl group of four carbons or feWer. 
For example, R1 and R2 include pyrrole, pyrrolidine, pyra 
Zole, imidaZole, oxaZole, isoxaZole, thiaZole, isothiaZole, 
oxadiaZole, oxatriaZole, dioxaZole, 1,2,3-triazole, 1,2,4-tria 
Zole, pyridine, pyrimidine, piperidine, quinoline, tetrahydro 
quinoline, isoquinoline, tetrahydroisoquinoline, pyraZine, 
piperaZine, pyridaZine, triaZine, oxaZine, phenaZine, pteri 
dine, benZoxaZine, phthalaZine, naphthridine, quinoxaline, 
quinaZoline, cinnoline, quinuclidine, benZothiaZole, ben 
ZisoxaZole, benZoxaZole, indaZole, pyranopyrrole, cyclopen 
tapyridine, benZimidaZole, isoindole, 3H-indole, indolene 
and triaZine. 
As another example, R3, R4, R5, R6, R7, R8, R9, R10, R11, 
R12’ R14’ R15’ R16’ R17’ R18’ R19’ R20’ and R21’ include 
hydrogen, methyl, ethyl, propyl, butyl, hydroxymethyl, 
hydroxyethyl, hydroxypropyl, tri?uoromethyl, chloro, 
bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine (for example 
Where the alkyl chain is methyl, ethyl or propyl), unsaturated 
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pyrrolidine, unsaturated N-alkyl pyrrolidine (for example 
Where the alkyl chain is methyl, ethyl or propyl), aZiridine, 
N-methyl aZiridine, aZetidine, N-methyl aZetidine, unsatur 
ated aZetidine, unsaturated N-methyl aZetidine, piperidine, 
N-methyl piperidine, unsaturated piperidine, unsaturated 
N-methyl piperidine, aZepane, N-methyl aZepane, unsatur 
ated aZepane, unsaturated N-methyl aZepane, aZocane, 
N-methyl aZocane, unsaturated aZocane, unsaturated N-me 
thyl aZocane, l-aZa-bicyclo[3.2.l]octane, l-aZa-bicyclo 
[2.2.1]heptane, 8-methyl-8-aZa-bicyclo[3.2.l]octane, l-aZa 
tricyclo [3.3.1.13 ’7]decane, methyl cycloalkyl, methyl 
substituted cycloalkyl, methyl pyrrolidine, methyl N-alkyl 
pyrrolidine (for example Where the alkyl chain is methyl, 
ethyl or propyl), methyl unsaturated pyrrolidine, methyl 
unsaturated N-alkyl pyrrolidine (for example Where the alkyl 
chain is methyl, ethyl or propyl), methyl aZiridine, methyl 
N-methyl aZiridine, methyl aZetidine, methyl N-methyl aZe 
tidine, methyl unsaturated aZetidine, methyl unsaturated 
N-methyl aZetidine, methyl piperidine, methyl N-methyl pip 
eridine, methyl unsaturated piperidine, methyl unsaturated 
N-methyl piperidine, methyl aZepane, methyl N-methyl 
aZepane, methyl unsaturated aZepane, methyl unsaturated 
N-methyl aZepane, methyl aZocane, methyl N-methyl aZo 
cane, methyl unsaturated aZocane, methyl unsaturated N-me 
thyl aZocane, methyl-l-aZa-bicyclo[3.2.l]octane, methyl-l 
aZa-bicyclo[2.2.l]heptane, 8-methyl-8-aZa-bicyclo[3.2.l] 
octane, and methyl-l -aZa-tricyclo[3.3 .l .l3’7]decane. 
As a further example, When R4 and R5 together WithAl and 
A2, or R5 and R7 together With A2 and A3, or R15 and R16 
together With A6 and A7, or R16 and R18 together With A7 and 
A8 independently form a three to eight-membered ring, that 
ring may be a heterocycle containing up to three hetero atoms 
(for example nitrogen, oxygen or sulfur) in the ring, and 
further may be substituted With one or more substituents. For 
example, possible rings include benZene, pyridine, pyran, 
indene, isoindene, benZofuran, isobenZofuran, benZo [b] 
thiophene, benZo[c]thiophene, indole, indolenine, isoindole, 
cyclopental[b]pyridine, pyrano[3,4-b]pynrole, indaZole, 
indoxaZine, benZoxaZole, anthranil, naphthalene, tetralin, 
decalin, chromene, coumarin, chroman-4-one, isocoumarin, 
isochromen-3-one, quinoline, isoquinoline, cinnoline, 
quinaZoline, naphthyrdine, pyrido[3,4-b]-pyridine, pyridol 
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benZoxaZine, 
anthracene, phenanthrene, phenalene, ?uorene, caraZole, 
xanthene, acnidine, octahydro-[l]pyridine, l-methyloctahy 
dro-[l]pyridine, octahydroindole, l-methyloctahydro-in 
dole, octahydro-cyclopenta[b]pyrrole, l-methyloctahydro 
cyclopenta[b]pyrrole, decahydroquinoline, and 
l -met<l5yldecahydroquinoline. 
X1 and X2©, for example, include F', Cl“, Br“, I“, 
N02“, HSO4_, SO4_, HPO4_, PO42“, methanesulfonate, tri 
?uromethane sulfate, p-toluenesulfonate, benZenesulfonate, 
salicylate, proprionate, ascorbate, aspartate, fumarate, galac 
tarate, maleate, citrate, glutamate, glycolate, lactate, malate, 
maleate, tartrate, oxalate, succinate, or similar pharmaceuti 
cally acceptable organic acid addition salts, including the 
pharmaceutically acceptable salts listed in the Journal of 
Pharmaceutical Sciences volume 66, page 2, 1977, Which are 
hereby incorporated by reference. The above salt forms may 
be in some cases hydrates or solvates With alcohols and other 
solvents. 
In a compound of Formula (I), preferably R1 and R2 are 
substituted, six-membered, aromatic rings. More preferably, 
R1 and R2 are substituted pyridinium rings. In other preferred 
embodiments, R1 and R2 are quinoline, isoquinoline, tetrahy 
droquinoline or tetrahydroisoquinoline. 
In a compound of Formula (I), preferably R13 is absent. 
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In a compound of Formula (I), preferably R3, R4, R5, R6, 
R7, R8, R9, R10, R11 or R12 is absent or is hydrogen, alkyl, 
hydroxyalkyl, halo, phenyl or l-alkyl-2-pyrrolidinyl. More 
preferably, R3, R4, R5, R6, R7, R8, R9, R10, R11 or R12 is absent 
or is hydrogen, methyl, ethyl, propyl, butyl, hydroxymethyl, 
hydroxyethyl, hydroxypropyl, bromo, phenyl or l-methyl-2 
pyrrolidinyl. 
In a compound of Formula (I), preferably Q is phenylene, 
biphenylene, iCH:CH4CH:CHi, iC5C4CECi 
and iOi(CH2)2iOi(CH2)2A)i. 
In a compound of Formula (I), preferably L1 and L2 are the 
same and are 4CH2i, i(CH2)2i, i(CH2)3i, 
i(CH2)4i, %ECi, %H2%ECi or i(CH2)2i 
CECi 
In a compound of Formula (I), referablyQXlQ and X2© 
are halogens. More preferably, X1 and X2 are chloride or 
bromide. 
In another embodiment, the compound of Formula (I) is 
de?ned Wherein -Ll-Q-L2- is 4CH2)4-l,2-phenylene 
(CH2)4*s *(CH2)4'1s3'Pheny1ene'(CH2)4*s i(CH2)3_1s 
4-phenylene-(CH2)3i, i(CH2)2-4,4'-biphenylene 
(CH2)2i, i(CH2)2iCEC-l ,2-phenylene-CECi 
(CH2)2i, i(CH2)2iCEC-l ,3 -phenylene-CECi 
(CH2)2i, 4CH24CEC-l ,4-phenylene-CECiCH2i, 
4CEC-4,4'-biphenylene-CECi, i(CH2)34CH:CHi 
CH:CHi(CH2)3i, i(CH2)3iC5C4CECi 
(CH2)3* or 4CH24O*(CH2)2*O*(CH2)2*O* 
CHzi, R1 and R2 are pyridinium rings, R3 is hydrogen or 
methyl, R5 is hydrogen, methyl, ethyl, butyl, phenyl, l-me 
thyl-2-pyrrolidinyl, bromo, hydroxymethyl or hydroxypro 
pyl, R7 is hydrogen or methyl, R9 is hydrogen or methyl, R1 1 
is hydrogen, and X1 and X2 are chloride or bromide. 
In another embodiment, the compound of Formula (I) is 
de?ned Wherein -Ll-Q-L2- is i(CH2)4-l,2-phenylene 
(CH2)4*> *(CH2)4'1>3'Pheny1ene'(CH2 4*: *(CH2)3'1, 
4-phenylene-(CH2)3i, i(CH2)2-4,4'-biphenylene 
(CH2)2*, i(CH2)2iCEC-l ,2-phenylene-CECi 
(CH2)2*, i(CH2)2iCEC-l ,3 -phenylene-CECi 
(CH2)2*, iCHziCgC-l ,4-phenylene-CECH2i, 
4CEC-4,4'-biphenylene-C:CECi, i(CH2)3i 
CH:CHiCH:CHi(CH2)3i, i(CH2)34CECi 
O4CH2i, R1 and R2 are quinoline, isoquinoline, 
tetrahydroquinoline or tetrahydroisoquinoline, and X1 and X2 
are chloride or bromide. 
Exemplary compounds of the present invention include: 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-[3 -(2'-S- l - 
methyl-pyrrolidin-2 -yl)-pyridinium]dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(2-methyl 
pyridinium) dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(3 -methyl 
pyridinium) dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(4-methyl 
pyridinium) dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(5 ,6,7,8-tet 
rahydro -quinolinium)dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(5 ,6,7,8-tet 
rahydro -isoquinolinium)dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(2,4-dim 
ethyl-pyridinium) dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(3 ,4-dim 
ethyl-pyridinium) dibromide; 
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(3 ,5 -dim 
ethyl-pyridinium) dibromide; 
N,N'- [l ,4-phenylenedi-(4 -butanyl)] -bis-[3-(2'-S-l -methyl 
pyrrolidin-2 -yl) -pyridinium] dibromide; 
N,N'- [l ,4-phenylenedi-(4 -butanyl)] -bis-(2-methylpyri 
dinium) dibromide; 
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N,N'-(5 ,7-dodecadiyn-1 ,12-diyl)-bis-(4-methylpyridinium) 
dichloride; 
N,N'-(5,7-dodecadiyn-1,12-diyl)-bis-(3,4-dimethylpyri 
dinium)dichloride; 
N,N'-(5,7-dodecadiyn-1,12-diyl)-bis-(3,5 -dimethylpyri 
dinium)dichloride; 
N,N'-(5,7-dodecadiyn-1,12-diyl)-bis-(5,6,7,8-tetrahydroiso 
quinolinium)dichloride; 
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(3-methyl-pyri 
dinium)dibromide; 
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(4-methyl-pyri 
dinium)dibromide; 
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(5,6,7,8-tetrahy 
droisoquiolinium)dibromide; 
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(3,4-dimethyl 
pyridinium)dibromide; 
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(3,5 -dimethyl 
pyridinium)dibromide; 
N,N'-[(1,1'-biphenyl)-4,4'-di-(1-propyn-3 -yl)] -bis-(3 -meth 
ylpyridinium)dibromide; 
N,N'-[(1,1'-biphenyl)-4,4'-di-(1-propyn-3 -yl)] -bis-(4 -meth 
ylpyridinium)dibromide; 
N,N'-[(1,1'-biphenyl)-4,4'-di-(1-propyn-3-yl)]-bis-(3,4-dim 
ethylpyridinium)dibromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as Well as all com 
binations of diastereomers and enantiomers, including race 
mic mixtures. The compounds can be separated into substan 
tially optically pure compounds. 
The compounds of the invention are nicotinic acetylcho 
line receptor agents. Thus, they may augment or inhibit 
[3H]iS-nicotine binding, [3H]MLA binding, evoke or 
inhibit neurotransmitter release, and/or evoke or inhibit the 
?ux of ions through the nicotinic receptor. Moreover, the 
compounds of the invention may act either at presynaptic 
sites or postsynaptic sites, for example, at a postsynaptic 
acetylcholine receptor containing an (X7 subunit. When acting 
at a postsynaptic site, neurotransmitter release per se is not 
altered. Rather, the compounds of the invention may act by 
interacting With a postsynaptic acetylcholine receptor to 
change the membrane potential of the cell, thereby increasing 
or decreasing the likelihood of ?ring an action potential. 
Alternatively, interaction of a compound of the invention With 
a postsynaptic acetylcholine receptor may result in the alter 
ation of one or more second messenger systems Within the 
cell so as to decrease or increase the nicotinic cholinergic 
response. 
In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agoinst or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
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mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agoinst or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
Central nervous system disorders Which may be treated 
according to the method of the present invention include 
AlZheimer’s disease, dementia, cognitive dysfunctions (in 
cluding disorders of attention, focus and concentration), 
attention de?cit disorders, affective disorders, extrapyrami 
dal motor function disorders, Parkinson’s disease, progres 
sive supramolecular palsy, Huntington’s disease, Gilles de la 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis 
orders, dysregulation of food intake, disorders of nociception, 
pain, mood and emotional disorders, depression, panic anxi 
ety, psychosis, schiZophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating sub stance 
use and/or abuse comprising administering to a mammalian 
subject in need thereof a therapeutically effective amount of a 
compound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agoinst or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
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mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet 
amine abuse, MDMA (methylenedioxymethamphetamine) 
abuse, methylphenidate abuse, cocaine abuse, or alcohol 
abuse. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating gastrointestinal tract 
disorders comprising administering to a mammalian subject 
in need thereof a therapeutically effective amount of a com 
pound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue, or may increase 
or prolong the release of a neurotransmitter from a peripheral 
nervous system tissue, or may act directly on a gastrointesti 
nal tract tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act as an antagonist of nicotinic acetylcholine recep 
tor function. Hence the compound of Formula (I) may 
decrease the extent or duration of the release of a neurotrans 
mitter from a central nervous system tissue, or may decrease 
the extent or duration of the release of a neurotransmitter from 
a peripheral nervous system tissue, or may act directly on a 
gastrointestinal tract tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu 
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutryic acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting With a postsynaptic ace 
tylcholine receptor to change the membrane potential of the 
cell thereby increasing or decreasing the likelihood of ?ring 
an action potential, or to alter one or more second messenger 
systems Within the cell so as to decrease or increase the 
nicotinic cholinergic response. 
Gastrointestinal disorders Which may be treated according 
to the method of the present invention include irritable boWel 
syndrome, colitis, diarrhea, constipation, gastric acid secre 
tion or ulcers. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating in?am 
matory tract disorders comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agonist or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue, or may 
increase or prolong the release of a neurotransmitter from a 
peripheral nervous system tissue, or may act directly on a 
non-nervous system tissue. The neurotransmitter affected 
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may include dopamine, norepinephrine, serotonin, gamma 
aminobutryic acid, or glutamate. Alternatively, the compound 
of Formula (I) may act as an antagonist of nicotinic acetyl 
choline receptor function. Hence the compound of Formula 
(I) may decrease the extent or duration of the release of a 
neurotransmitter from a central nervous system tissue, or may 
decrease the extent or duration of the release of a neurotrans 
mitter from a peripheral nervous system tissue, or may act 
directly on a non-nervous system tissue. In this regard, the 
compound of Formula (I) may act by decreasing stimulant 
evoked neurotransmitter release. The neurotransmitter 
affected may include dopamine, norepinephrine, serotonin, 
gamma-aminobutryic acid, or glutamate. Alternatively, the 
compound of Formula (I) may act by interacting With a 
postsynaptic acetylcholine receptor to change the membrane 
potential of the cell thereby increasing or decreasing the 
likelihood of ?ring an action potential, or to alter one or more 
second messenger systems Within the cell so as to decrease or 
increase the nicotinic cholinergic response. 
In?ammatory disorders Which may be treated according to 
the method of the present invention include adult respiratory 
distress syndrome, allergy, anemia, ankylosing spondylitis, 
asthma, atherosclerosis, bacterial infections, benign prostatic 
hyperplasia, cholecystitis, ulcerative colitis, Crohn’s disease, 
diabetes mellitus, emphysema, gastritis, glomerulonephritis, 
hypereosinophilia, irritable boWel syndrome, multiple scle 
rosis, osteoarthritis, pancreatitis, polymyositis, psoriasis and 
rheumatoid arthritis. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along With suit 
able carriers or excipients, as is Well knoWn in the art. For 
example, a pharmaceutical composition of the invention may 
include a conventional additive, such as a stabiliZer, buffer, 
salt, preservative, ?ller, ?avor enancer and the like, as knoWn 
to those skilled in the art. Exemplary buffers include phos 
phates, carbonates, citrates and the like. Exemplary preserva 
tives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter 
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro 
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington’s Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, nasal, or intestinal admin 
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as Well as intrathe 
cal, direct intraventricular, intravenous, intraperitoneal, intra 
nasal, or intraocular injections. In addition, the agent or com 
position thereof may be administered sublingually or via a 
spray, including a sublingual tablet or a sublingual spray. The 
agent or composition thereof may be administered in a local 
rather than a systemic manner. For example, a suitable agent 
can be delivered via injection or in a targeted drug delivery 
system, such as a depot or sustained release formulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods Well-knoWn in 
the art, such as by conventional mixing, dissolving, granulat 
ing, dragee-making, levigating, emulsifying, encapsulating, 
entrapping, or lyophiliZing processes. As noted above, the 
compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin 
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in physi 
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ologically compatible buffers such as Hanks’ solution, Ring 
er’ s solution, or physiological saline buffer. For transmucosal 
or nasal administration, penetrants appropriate to the barrier 
to be permeated are used in the formulation. Such penetrants 
are generally knoWn in the art. In a preferred embodiment of 
the present invention the present compounds are prepared in 
a formulation intended for oral administration. For oral 
administration, the compounds can be formulated readily by 
combining the active compounds With pharmaceutically 
acceptable carriers Well knoWn in the art. Such carriers enable 
the compounds of the invention to be formulated as tablets, 
pills, dragees, capsules, liquids, gels, syrups, slurries, suspen 
sions and the like, for oral ingestion by a subject. The com 
pounds may also be formulated in rectal compositions such as 
suppositories or retention enemas, e.g., containing conven 
tional suppository bases such as cocoa butter or other glyc 
erides. 
Pharmaceutical preparations for oral use canbe obtained as 
solid excipients, optionally grinding a resulting mixture, and 
processing the mixture of granules, after adding suitable aux 
iliaries, if desired, to obtain tablets or dragee cores. Suitable 
excipients are, in particular, ?llers such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; cellulose preparations 
such as, for example, maiZe starch, Wheat starch, rice starch, 
potato starch, gelatin, gum tragacanth, methyl cellulose, 
hydroxypropylmethyl-cellulose, sodium carboxymethylcel 
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin 
tegrating agents may be added, such as the cross-linked poly 
vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as 
sodium alginate. Also, Wetting agents such as sodium dodecyl 
sulfate may be included. 
Dragee cores are provided With suitable coatings. For this 
purpose, concentrated sugar solutions may be used, Which 
may optionally contain gum arabic, talc, polyvinyl pyrroli 
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identi?cation or to characteriZe 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-?t capsules made of gelatin, as Well as soft, 
sealed capsules made of gelatin and a plasticiZer, such as 
glycerol or sorbitol. The push-?t capsules can contain the 
active ingredients in admixture With ?ller such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabiliZers. In soft cap 
sules, the active compounds may be dissolved or suspended in 
suitable liquids, such as fatty oils, liquid paraf?n, or liquid 
polyethylene glycols. In addition, stabiliZers may be added. 
All formulations for oral administration should be in dosages 
suitable for such administration. 
In one embodiment, the compounds of the present inven 
tion can be administered transdermally, such as through a skin 
patch, or topically. In one aspect, the transdermal or topical 
formulations of the present invention can additionally com 
prise one or multiple penetration enancers or other effectors, 
including agents that enhance migration of the delivered com 
pound. Transderrnal or topical administration could be pre 
ferred, for example, in situations in Which location speci?c 
delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebuliZer, With the use of a suitable propellant, e.g., 
dichlorodi?uoromethane, trichloro?uoromethane, dichlo 
rotetra?uoroethane, carbon dioxide, or any other suitable gas. 
In the case of a pressurized aerosol, the appropriate dosage 
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unit may be determined by providing a valve to deliver a 
metered amount. Capsules and cartridges of, for example, 
gelatin, for use in an inhaler or insuf?ator may be formulated. 
These typically contain a poWder mix of the compound and a 
suitable poWder base such as lactose or starch. 
Compositions formulated for parenteral administration by 
injection, e. g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, With an added preservative. The com 
positions may take such forms as suspensions, solutions, or 
emulsions in oily or aqueous vehicles, and may contain for 
mulatory agents such as suspending, stabiliZing and/or dis 
persing agents. Formulations for parenteral administration 
include aqueous solutions or other compositions in Water 
soluble form. 
Suspensions of the active compounds may also be prepared 
as appropriate oily injection suspensions. Suitable lipophilic 
solvents or vehicles include fatty oils such as sesame oil and 
synthetic fatty acid esters, such as ethyl oleate or triglycer 
ides, or liposomes. Aqueous injection suspensions may con 
tain substances that increase the viscosity of the suspension, 
such as sodium carboxymethyl cellulose, sorbitol, or dextran. 
Optionally, the suspension may also contain suitable stabiliZ 
ers or agents that increase the solubility of the compounds to 
alloW for the preparation of highly concentrated solutions. 
Alternatively, the active ingredient may be in poWder form for 
constitution With a suitable vehicle, e.g., sterile pyrogen-free 
Water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu 
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated With suitable poly 
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are Well knoWn in the art and include co-solvent 
systems comprising, for example, benZyl alcohol, a nonpolar 
surfactant, a Water-miscible organic polymer, and an aqueous 
phase. The co-solvent system may be the VPD co-solvent 
system. VPD is a solution of 3% W/v benZyl alcohol, 8% W/v 
of the nonpolar surfactant polysorbate 80, and 65% W/v poly 
ethylene glycol 300, made up to volume in absolute ethanol. 
The VPD co-solvent system (VPDzSW) consists of VPD 
diluted 1:1 With a 5% dextrose in Water solution. This co 
solvent system is effective in dissolving hydrophobic com 
pounds and produces loW toxicity upon systemic administra 
tion. Naturally, the proportions of a co-solvent system may be 
varied considerably Without destroying its solubility and tox 
icity characteristics. Furthermore, the identity of the co-sol 
vent components may be varied. For example, other loW 
toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction siZe of polyethylene glycol may 
be varied, other biocompatible polymers may replace poly 
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars 
or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic mol 
ecules may be employed. Liposomes and emulsions are Well 
knoWn examples of delivery vehicles or carriers for hydro 
phobic drugs. Liposomal delivery systems are discussed 
above in the context of gene-delivery systems. Certain 
organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus 
tained-release systems, such as semi-permeable matrices of 
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solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained 
release materials are established and available to those of skill 
in the art. Sustained-release capsules may, depending on their 
chemical nature, release the compounds for a feW Weeks up to 
over 100 days. Depending on the chemical nature and the 
biological stability of the therapeutic reagent, additional 
strategies for stabiliZation may be employed. 
For any composition used in the present methods of treat 
ment, a therapeutically effective dose can be estimated ini 
tially using a variety of techniques Well knoWn in the art. For 
example, in a cell culture assay, a dose can be formulated in 
animal models to achieve a circulating concentration range 
that includes the 1C5O as determined in cell culture. Dosage 
ranges appropriate for human subjects can be determined, for 
example, using data obtained from cell culture assays and 
other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 
or a prolongation of survival in a subject. Toxicity and thera 
peutic ef?cacy of such molecules can be determined by stan 
dard pharmaceutical procedures in cell cultures or experi 
mental animals, e. g., by determining the LD5O (the dose lethal 
to 50% of the population) and the ED5O (the dose therapeuti 
cally effective in 50% of the population). The dose ratio of 
toxic to therapeutic effects is the therapeutic index, Which can 
be expressed as the ratio LDSO/EDSO. Agents that exhibit high 
therapeutic indices are preferred. 
Dosages preferably fall Within a range of circulating con 
centrations that includes the ED5O With little or no toxicity. 
Dosages may vary Within this range depending upon the 
dosage form employed and the route of administration uti 
liZed. The exact formulation, route of administration, and 
dosage should be chosen, according to methods knoWn in the 
art, in vieW of the speci?cs of a subject’s condition. 
The amount of agent or composition administered Will, of 
course, be dependent on a variety of factors, including the sex, 
age, and Weight of the subject being treated, the severity of the 
af?iction, the manner of administration, and the judgment of 
the prescribing physician. 
The present compositions may, if desired, be presented in a 
pack or dispenser device containing one or more unit dosage 
forms containing the active ingredient. Such a pack or device 
may, for example, comprise metal or plastic foil, such as a 
blister pack. The pack or dispenser device may be accompa 
nied by instructions for administration. Compositions com 
prising a compound of the invention formulated in a compat 
ible pharmaceutical carrier may also be prepared, placed in an 
appropriate container, and labeled for treatment of an indi 
cated condition. 
These and other embodiments of the present invention Will 
readily occur to those of ordinary skill in the art in vieW of the 
disclosure herein, and are speci?cally contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
folloWing examples, Which are intended to be purely exem 
plary of the invention. The present invention is not limited in 
scope by the exempli?ed embodiments, Which are intended as 
illustrations of single aspects of the invention only. Any meth 
ods that are functionally equivalent are Within the scope of the 
invention. Various modi?cations of the invention in addition 
to those described herein Will become apparent to those 
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skilled in the art from the foregoing description. Such modi 
?cations fall Within the scope of the appended claims. 
Example 1 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1 , 12-diyl)-bis- [3 -(2'-S-1-methyl-pyrrolidin-2 
yl)-pyridinium]dibromide 
/ Br 
Br / 
+ —> 
\ N I \ 
CH3 / 
N 
N/CH3 
/ N@— \ \ / / @ NW
H3C—N 
cis-cis-1,12-Dibromo-dodeca-5,7-diene (1 mmol) Was 
added to a solution of S-nicotine (3 mmol) in acetonitrile and 
the solution re?uxed for 24 hours. The acetonitrile Was 
removed in vacuum and the resulting residue Was partitioned 
betWeen ether and Water. The aqueous layer Was Washed 
extensively With ether until no S-nicotine left in the aqueous 
layer. The resulting aqueous solution of the product Was lyo 
philiZed to yieldthe pure product. (70%). lHNMR (300 MHZ, 
D20, ppm) 8.60 (s, 2H), 8.59 (d, 2H), 8.32 (d, 1:84, 2H), 7.88 
(t, 1:57, 2H), 6.12-6.20 (m, 2H), 5.30-5.40 (m, 2H), 4.43 (t, 
J:7.2, 4H), 3.39 (t, 1:84, 2H), 3.01-3.06 (m, 2H), 2.16-2.34 
(m, 4H), 2.01-2.09 (m, 10H), 1.64-1.88 (m, 10H), 1.25 (p, 
1:75, 4H). l3CNMR, 144.67, 143.35, 132.20, 128.45, 
124.12, 67.65, 62.05, 56.65, 39.41, 33.76, 30.32, 26.34, 
25.47, 22.36. 
Example 2 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1 ,12-diyl)-bis-(2-methyl-pyridinium)dibro 
mide 
Br 
Br 
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-continued _ 
/ N® 
/ (3N / 213,6 \ / 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 2-picoline (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no picoline left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (76%). lHNMR (300 MHZ, D20, 
ppm) 8.52 (dd, 1:63, 2H), 8.17 (dt, 1:78, 1:15, 2H), 7.72 
(d, J:7.8, 2H), 7.64 (t, 1:63, 2H), 6.18-6.23 (m, 2H), 5.33 
5.41 (m, 2H), 4.37 (t, J:7.1, 4H), 2.66 (s, 6H), 2.09 (q, 1:75, 
4H), 1.72-1.82 (m, 4H), 1.36 (p, 1:75, 4H). l3CNMR, 
155.26, 145.01, 144.73, 132.25, 130.23, 125.64, 124.15, 
58.06, 29.10, 26.38, 25.61, 19.73. 
Example 3 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1,12-diyl)-bis-(3-methyl-pyridinium)dibro 
mide 
/ Br + 
Br / 
T9 /
N 
/ N @— 
/ ®\N / 2B1 9 / 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 3-picoline (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no picoline left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (76%). lHNMR (300 MHZ, D20, 
ppm) 8.50 (s, 2H), 8.44 (d, 1:63, 2H), 8.16 (d, J:7.8, 2H), 
7.74 (dd, 1:78, 1:63, 2H), 6.15-6.18 (m, 2H), 5.38-5.38 (m, 
2H), 4.38 (t, 1:57, 4H), 2.35 (s, 6H), 2.06 (q, 1:75, 4H), 1.83 
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(p, 1:75, 4H), 1.25 (p, 1:75, 4H). l3cNMR, 145.99, 143.71, 
141.30, 139.95, 132.19, 127.46, 124.06, 61.69, 30.27, 26.35, 
25.44, 17.93. 
Example 4 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1 ,12-diyl)-bis-(4-methyl-pyridinium)dibro 
mide 
/ Br + 
Br / 
E9 /
N 
/ No 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 4-picoline (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no picoline left in the aqueous layer The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.45 (d, 1:69, 4H), 7.68 (d, 1:69, 4H), 6.14-6.19 (m, 
2H), 5.31-5.39 (m, 2H), 4.35 (t, J:7.2, 4H), 2.47 (s, 6H), 2.07 
(q, J:7.2, 4H), 1.83 (p, 1:75, 4H), 1.25 (p, 1:75, 4H). 
Example 5 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1,12-diyl)-bis-(5,6,7,8-tetrahydro-quino 
linium)dibromide 
/ Br 
+ 
Br / 
\ | / 
N 
/ N (D 
/ \ W\ / i (9 N / 5 E 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 5,6,7,8-tetrahydro-quinoline (3 mmol) in acetoni 
trile and the solution re?uxed for 24 hours. The acetonitrile 
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Was removed in vacuum and the resulting residue Was parti 
tioned between ether and Water. The aqueous layer Was 
Washed extensively With ether until no quinoline left in the 
aqueous layer. The resulting aqueous solution of the product 
Was lyophiliZed to yield the pure product. (75%). lHNMR 
(300 MHZ, D20, ppm), 8.35 (d, 1:63, 2H), 7.97 (d, 1:81, 
2H), 7.52 (dd, 1:81, 1:63, 2H), 6.16-6.22 (m, 2H), 5.32 
5.42 (m, 2H), 4.30 (t, J:7.8, 4H), 2.92 (t, 1:62, 4H), 2.79 (t, 
1:62, 4H), 2.09 (q, J:7.2, 4H), 1.60-1.83 (m, 12H), 1.36 (p, 
1:75, 4H). 
Example 6 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1,12-diyl)-bis-(5,6,7,8-tetrahydro-isoquino 
linium)dibromide 
/ 
/ 
\ —> 
| N/ 
/ N 6 C(QNW Cb 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 5,6,7,8-tetrahydro-isoquinoline (3 mmol) in 
acetonitrile and the solution re?uxed for 24 hours. The aceto 
nitrile Was removed in vacuum and the resulting residue Was 
partitioned betWeen ether and Water. The aqueous layer Was 
Washed extensively With ether until no isoquinoline left in the 
aqueous layer. The resulting aqueous solution of the product 
Was lyophiliZed to yield the pure product. (75%). lHNMR 
(300 MHZ, D20, ppm), 8.30 (s, 2H), 8.19 (d, 1:66, 2H), 7.50 
(d, 1:63, 2H), 6.09-6.16 (m, 2H), 5.28-5.36 (m, 2H), 4.27 (t, 
J:7.2, 4H), 2.29-2.82 (hr, 4H), 2.67-2.74 (br, 4H), 2.02 (q, 
J:7.2, 4H), 1.81 (p, 1:72, 4H), 1.62-1.69 (m, 8H), 1.22 (p, 
1:72, 4H). CNMR158.82, 143.10, 139.60, 138.96, 132.28, 
127.92, 124.09, 60.82, 49.13, 30.07, 29.35, 26.32, 26.20, 
25.43, 21.01. 
Br 
Example 7 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene- 1 ,12-diyl)-bis-(2,4-dimethyl-pyridinium)dibro 
mide 
Br 
Br 
5 
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-continued 
b / N 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 2,4-lutidine (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 2,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.31 (d, 1:63, 2H), 7.53 (s, 2H), 7.46 (d, 1:69, 2H), 
6.16-6.22 (m, 2H), 5.32-5.40 (m, 2H), 4.28 (t, 1:81, 4H), 
2.58 (s, 3H), 2.38 (s, 3H), 2.07 (q, J:7.2, 4H), 1.74 (p, 1:75, 
4H), 1.33 (p, 1:75, 4H). CNMR, 159.20, 153.87, 143.69, 
132.32, 130.44, 126.34, 124.18, 57.19, 29.10, 26.41, 25.63, 
21.19,19.46. 
Example 8 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene-1, 12-diyl)-bis-(3,4-dimethyl-pyridinium)dibro 
mide 
/ Br 
+ 
Br / 
Ti /
N 
/ Ne) 
/® \N / ZBre \ / 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 3,4-lutidine (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 3,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.34 (s, 1H), 8.29 (d, 1:63, 1H), 7.60 (d, 1:63, 1H), 
6.13-6.18 (m, 2H), 5.30-5.38 (m, 2H), 4.31 (t, 1:72, 4H), 
2.37 (s, 3H), 2.25 (s, 3H), 2.05 (q, J:7.2, 4H), 1.81 (p, 1:75, 
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4H), 1.24 (p, 1:75, 4H). CNMR, 158.66, 142.37, 140.71, 
138.65, 132.25, 128.23, 124.07, 60.80, 30.11, 26.31, 25.42, 
19.69, 16.34. 
Example 9 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7 
diene- 1 ,12-diyl)-bis-(3,5-dimethyl-pyridinium)dibro 
mide 
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a 
solution of 3,5-lutidine (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned between 
ether and Water. The aqueous layer.Was Washed extensively 
With ether until no 3,5-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.29 (s, 4H), 7.99 (s, 2H), 6.12-6.18 (m, 2H), 5.30-5.38 
(m, 2H), 4.31 (t, 1:75, 4H), 2.30 (s, 6H), 2.05 (q, J:7.2, 4H), 
1.81 (p, 1:75, 4H), 1.24 (p, 1:75, 4H). CNMR, 146.56, 
140.96, 139.11, 132.28, 124.09, 61.49, 30.21, 26.34, 25.43, 
17.73. 
Br 
Br 
Example 10 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)] -bis- [3 -(2'-S-1-methyl-pyrrolidin-2-yl) 
pyridinium] dibromide 
BIWQNBI —> 
H3C 
21319 
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1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of S-nicotine (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no S-nicotine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.57-8.59 (m, 4H), 8.35 (d, 1:81, 2H), 7.88 (dd, 1:78, 
1:66, 2H), 7.01 (s, 4H), 4.45 (t, 1:75, 4H), 3.40 (t, 2H), 
3.04-3.10 (m, 2H), 2.49 (t, 1:75, 4H), 2.30-2.40 (m, 2H), 
2.18-2.29 (m, 2H), 2.03 (s, 6H), 1.80-1.90 (m, 8H), 1.40-1.55 
(m, 4H). CNMR, 144.65, 143.48, 143.30, 139.76, 128.74, 
128.42, 67.61, 61.99, 56.62, 39.37, 33.96, 33.73, 30.17, 
27.28, 22.33. 
Example 11 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)] -bis -(2 -methylpyri dinium)dibromide 
BIWQMBI —> 
\ 
/ ZBre / 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 2-picoline (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 2-picoline left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.49 (dd, 1:60, 1.2, 2H), 8.17 (dt, 1:81, 1:15, 2H), 
7.70 (d, 1:81, 2H), 7.65 (dt, 1:81, 1:12, 2H), 7.04 (s, 4H), 
4.37 (t, 1:72, 4H), 2.62 (s, 6H), 2.51 (t, 1:72, 4H), 1.77 (p, 
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127.8, 4H), 1.57 (p, 127.8, 4H). CNMR. 145.05, 144.73, 
139.79, 130.24, 128.78, 125.64, 58.02, 34.11, 29.01, 27.49, 
19.70. 
Example 12 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-(3 -methylpyridinium)dibromide 
BI/WQNBI —> 
@WQNW / /ZBre 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 3-picoline (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 3-picoline left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.45 (s, 2H), 8.40 (d, 126.6, 2H), 8.16 (d, 128.1, 2H), 
7.72 (dd, 128.1, 126.0, 2H), 7.00 (s, 4H), 4.37 (t, 127.5, 4H), 
2.47 (t, 127.5, 4H), 2.34 (s, 6H), 1.82 (p, 127.5, 4H), 1.46 (p, 
127.5, 4H). CNMR. 146.02,143.68, 141.68,139.96, 139.79, 
128.75, 127.46, 61.69, 34.04, 30.14, 27.28, 17.90. 
Example 13 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-(4-methylpyridinium)dibromide 
4 
\ 
/ / 
2Br e 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 4-picoline (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 4-picoline left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.38 (d, 126.9, 4H), 7.64 (d, 126.9, 4H), 6.98 (s, 4H), 
4.33 (t, 127.2, 4H), 2.46 (t, 127.2, 4H), 2.44 (s, 6H), 1.81 (p, 
20 
28 
1:75, 4H), 1.45 (p, 1:75, 4H). CNMR. 159.99, 143.04, 
139.79, 128.74, 128.65, 60.99, 34.02, 30.03, 27.26, 21.50. 
Example 14 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-(3-ethylpyridinium)dibromide 
Br/WQM Br _> 
\ | @ NW1.» / / 
2Br e 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 3-ethylpyridine (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
5 vacuum and the resulting residue Was partitioned betWeen 
35 
40 
45 
50 
60 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 3-ethylpyridine left in the aqueous layer. 
The resulting aqueous solution of the product Was lyophiliZed 
to yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.45 (s, 2H), 8.41 (d, 1-6.0, 2H), 8.19 (d, 128.4, 2H), 
7.73 (dd, 128.1, 126.0, 2H), 6.97 (s, 4H), 4.37 (t, 127.2, 4H), 
2.66 (q, 7.8, 2H), 2.49 (t, 127.2, 1.83 (p, 127.5, 4H), 1.45 (p, 
1-1.5, 4H), 1.09 (t, 127.8, 6H). CNMR. 145.61, 145.08, 
143.09, 141.51, 139.78, 128.75, 127.68, 61.70, 34.01, 30.13, 
27.24, 25.70, 13.92. 
Example 15 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)] -bis-(5, 6,7, 8-tetrahydroquinolinium)dibro 
mide 
(E / 2Bre / 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of tetrahydroquinoline (3 mmol) in acetonitrile and the solu 
tion re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no tetrahydroquinoline left in the aqueous 
layer. The resulting aqueous solution of the product Was lyo 
philiZed to yieldthe pure product. (75%). lHNMR (300 MHZ, 
D20, ppm), 8.30 (d, 126.3, 2H), 7.95 (d, 127.8, 2H), 7.49 (dd, 
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1:81, 1:63, 2H), 7.02 (s, 4H), 4.28 (I, 7.5, 4H), 2.83 (I, 
1:75, 4H), 2.77 (I, 1:75, 4H), 2.49 (I, 1:75, 4H), 1.66-1.80 
(m, 8H), 1.35-1.63 (m, 8H). 
Example 16 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)] -bis-(5, 6,7, 8-tetrahydroisoquinolinium) 
dibromide 
BI/WQNBI —> 
\ 
/ / 
ZBre 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of tetrahydroisoquinoline (3 mmol) in acetonitrile and the 
solution re?uxed for 24 hours. The acetonitrile Was removed 
in vacuum and the resulting residue Was partitioned between 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no tetrahydroisoquinoline left in the aqueous 
layer. The resulting aqueous solution of the product Was lyo 
philiZed to yieldthe pure product. (75%). lHNMR (300 MHZ, 
D20, ppm), 8.21 (s, 2H), 8.13 (d, 1:63, 2H), 7.46 (d, 1:63, 
2H), 6.96 (s, 4H), 4.25 (t, 1:72, 4H), 2.2.78-2.84 (hr, 4H), 
2.63-2.70 (hr, 4H), 2.44 (t, 1:72, 4H), 1.78 (p, 1:75, 4H), 
1.64-1.70 (m, 8H), 1.42 (p, 1:75, 4H). CNMR, 158.77, 
143.03, 139.78, 139.56, 138.88, 128.72, 127.84, 60.79, 
49.11, 34.01, 29.91, 29.31, 27.16, 26.16, 20.99. 
Example 17 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-[3-(3 -hydroxy-propyl)-pyridinium] 
dibromide 
BIWQMBI —> 
30 
35 
40 
45 
30 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of (3-hydroxy-propyl)-pyridine (3 mmol) in acetonitrile and 
the solution re?uxed for 24 hours. The acetonitrile Was 
removed in vacuum and the resulting residue Was partitioned 
betWeen ether and Water. The aqueous layer Was Washed 
extensively With ether until no (3 -hydroxy-propyl)-pyridine 
left in the aqueous layer. The resulting aqueous solution of the 
product Was lyophiliZed to yield the pure product. (75%). 
lHNMR (300 MHZ, D20, ppm), 8.49 (s, 2H), 8.43 (d, 1:60, 
2H), 8.22 (d, 1:81, 2H), 7.75 (dd, 1:78, 1:60, 2H), 6.98 (s, 
4H), 4.38 (t, J:7.2, 4H), 3.45 (t, 1:66, 4H), 2.72 (t, 1:78, 
4H), 2.46 (t, 1:75, 4H), 1.83 (p, 1:75, 4H), 1.70-1.75 )m, 
4H), 1.44 (p, 1:75, 4H). CNMR, 145.53, 143.51, 141.78, 
139.78, 128.75, 127.78, 61.75, 60.67, 34.01, 32.17, 30.13, 
28.81, 27.24. 
Example 18 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-(2,4-dimethylpyridinium)dibromide 
BIWQM Br _) 
\ 
/ / 
ZBre 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 2,4-lutidine (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 2,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, D20, 
ppm), 8.27 (d, 1:66, 2H), 7.50 (s, 2H), 7.45 (d, 1:66, 2H), 
HO / ZBIG / OH 
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7.02 (s, 4H), 4.28 (t, 1:72, 4H), 2.52 (s, 6H), 2.48 (t, 1:72, 
4H), 2.38 (s, 6H), 2.20 (s, 3H), 1.79 (p, 1:75, 4H), 1.42 (p, 
1:75, 4H). 
Example 19 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-(3,4-dimethylpyridinium)dibromide 
BIWQNBI _> 
/ / 
2Bre 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 3,4-lutidine (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 3,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, DZO, 
ppm), 8.25 (s, 2H), 8.22 (d, 1:60, 2H), 7.55 (d, 1:60, 2H), 
6.96 (s, 4H), 4.27 (t, 1:72, 4H), 2.45 (t, J:7.2, 4H), 2.34 (s, 
6H), 2.21 (s, 6H), 1.79 (p, 1:75, 4H), 1.42 (p, 1:75, 4H). 
CNMR, 158.64, 142.28, 140.66, 139.78, 138.61, 128.72, 
128.18, 34.02, 29.94, 27.20, 19.67, 16.29. 
Example 20 
Synthesis of Compound N,N'-[1,4-phenylenedi-(4 
butanyl)]-bis-(3,5-dimethylpyridinium)dibromide 
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution 
of 3,5-lutidine (3 mmol) in acetonitrile and the solution 
re?uxed for 24 hours. The acetonitrile Was removed in 
vacuum and the resulting residue Was partitioned betWeen 
ether and Water. The aqueous layer Was Washed extensively 
With ether until no 3,5-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product Was lyophiliZed to 
yield the pure product. (75%). lHNMR (300 MHZ, DZO, 
ppm), 8.23 (s, 4H), 7.97 (s, 2H), 6.97 (s, 4H), 4.29 (t, 1:72, 
4H), 2.45 (t, J:7.2, 4H), 2.27 (s, 12H), 1.81 (p, 1:75, 4H), 
30 
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1.45 (p, 1:75, CNMR, 146.50, 140.89, 139.79, 139.04, 
128.74, 61.46, 34.04, 30.03, 27.22, 17.70. 
Example 21 
Synthesis of Compound 5 -[2-(5 -hydroxy-pent-1 
ynyl)-phenyl]-pent-4-yn-1-ol 
OH % 
% OH 
1,2-DibromobenZene (10.94 g, 46.37 mmol), 4-pentyn-1 
01 (9.36 g, 111.30 mmol), and bis(triphenylphosphine)palla 
dium(ll) dichloride (650 mg, 0.93 mmol) Was stirred in tri 
ethylamine (150 mL) under nitrogen for 5 min. Copper(l) 
iodide (88 mg, 0.46 mmol) Was added and the mixture Was 
stirred for 4 hrs at 85° C. for 6 days. The mixture Was cooled 
to room temperature and ?ltered through a celite pad, rinsed 
With ethylacetate. The combined ?ltrate Was evaporated to 
dryness under reduced pressure. The resulting residue Was 
puri?ed by column chromatography (chloroformzmethanol 
30: 1) to afford 5.33 g of the title compound. Yield: 47%. 1H 
NMR (300 MHZ, D20) 6 1.85 (m, 4H), 2.58 (t, 1:66 HZ, 4H), 
3.82 (t, 1:60 HZ, 4H), 7.18 (m, 2H), 7.36 (m, 2H) ppm; 13C 
NMR (75 MHZ, CDCl3) 6 16.3, 31.4, 62.4, 80.2, 93.3, 126.0, 
127.4, 131.8 ppm. 
Example 22 
Synthesis of Compound 
1,2-bis-(5-bromo-pent-1-ynyl)-benZene 
% OH 
% OH 
% Br 
% Br 
5 -[2-(5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol 
(2.40 g, 9.90 mmol) and carbon tetrabromide (8.21 g, 24.75 
mmol) Were dissolved in dry methylene chloride (30 mL) and 
cooled to 00 C. Triphenyl phosphine (6.82 g, 25.99 mmol) in 
methylene chloride (15 mL) Was added dropWise and the 
mixture Was stirred for 1 h at 0° C. The mixture Was poured 
into hexanes (200 mL) and then ?ltered through a short silica 
gel column, Washed With ethylacetate/hexanes (1/4). The com 
bined organic solvents Were evaporated to dryness under 
reduced pressure. The resulting residue Was puri?ed by col 
umn chromatography (hexaneszethylacetate 30:1) to afford 
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2.48 g of the title compound. Yield: 68%. 1H NMR (300 MHZ, -Continued 
CDCl3) 6 2.16 (m, 4H), 2.68 (t, 1:66 HZ, 4H), 3.65 (dt, 1:66, 
0.6 HZ, 4H), 7.20 (m, 2H), 7.38 (m, 2H) ppm; 13C NMR (75 _ 
MHZ, CDCl3) 6 18.6, 31.8, 32.7, 80.7, 91.8, 125.9, 127.6, N@ 
131.9 ppm. 5 y \ / 
2B 9 I 
Example 23 _ 
% N® 
Synthesis of Compound 1,2-bis-[5-(2-methyl-pyri- 10 \ / 
dinium) -p ent-1 -ynyl] -b enZene dibromide 
A mixture of 1 ,2-bis-(5 -bromo-pent-1-ynyl)-benZene (270 
15 mg, 0.73 mmol) and 3-picoline (1 mL) Was heated at 60-70o 
% Br C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (15 mL), the aqueous solu 
tion Was extracted With diethyl ether (30 mL><3). Water Was 
20 removed by lyophiliZation to afford 350 mg of the title com 
% Br pound. Yield: 86%. 1H NMR (300 MHZ, CD3OD) 6 2.45 (m, 
4H), 2.56 (s, 6H) 2.78 (1, F66 HZ, 4H), 4.95 (r, J :72 HZ, 
4H), 7.22-7.42 (m, 4H), 8.05 (dd, 1:81, 6.0 HZ, 2H), 8.39 (d, 
1:78 HZ, 2H), 9.10 (d, 1:60 HZ, 2H), 9.19 (s, 2H) ppm; 13c 
,5 NMR (75 MHZ, @3013) 6 17.6, 18.9, 31.2, 61.9, 81.6, 92.8, 
126.4, 128.7, 129.0, 132.9, 140.9,143.1,145.6,147.3 ppm. 
N @ Exam le 25 / \ / p 
21319 30 
Synthesis of Compound 1,2-bis-[5-(4-methyl-pyri 
— dinium)-pent-l -ynyl]-benZene dibromide 
% NE) 
35 
/ Br 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (264 —> 
mg, 0.72 mmol) and 2-picoline (1 mL) Was heated at 60-700 
C. for 12 hrs. The resulted mixture Was Washed With diethyl 40 \ 
ether and then dissolved in Water (15 mL), the aqueous solu- Br 
tion Was extracted With diethyl ether (30 mL><3). Water Was 
removed by lyophiliZation to afford 327 mg of the title com 
pound.Yield: 82 %. 1H NMR (300 MHZ, CD3OD) 6 2.35 (m, 45 
4H), 2.81 (t, J :66 HZ, 4H), 3.02 (s, 6H), 4.91 (t, J :75 HZ, 
4H), 7.27-7.50 (m, 4H), 7.92-8.15 (m, 4H), 8.45 (t, J:7.8 HZ, 
2H), 9.11 (d, 1:63 HZ, 2H) m; 13C NMR (75 MHZ, CD3OD) 
6 17.6, 21.1, 30.1, 5.8.2, 81.9, 92.9, 126.4, 127.0, 129.2, _ 
129.3,131.5,133.1,146.4,156.7 ppm. 50 G) N 
Example 24 
% Synthesis of Compound 1,2-bis-[5-(3-methyl-pyri- 55 N ('3 
dinium) -pent-1 -ynyl] -benZene dibromide \ / 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (268 
60 mg, 0.73 mmol) and 4-picoline (1 mL) Was heated at 60-70o 
% Br C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (15 mL), the aqueous solu 
—’ tion Was extracted With diethyl ether (30 mL><3). Water Was 
removed by lyophiliZation to afford 435 mg of the title com 
% Br 65 pound. Yield: 86%. 1H NMR (300 MHZ, CD3OD) 6 2.41 (m, 
4H), 2.51 (s, 6H), 2.78 (1, F66 HZ, 4H 4.91 (1, F66 HZ, 4H), 
7.30 (s, 4H), 7.92 (d, 1:63 HZ, 4H), 9.05 (d, 1:63 HZ, 4H) 
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ppm; 13C NMR (75 MHZ, CD3OD) 6 17.5, 22.3, 31.0, 61.4, 
81.5, 92.8, 126.4, 129.0, 129.8, 132.9, 144.9, 161.1 ppm. 
Example 26 
Synthesis of Compound 1,2-bis-[5-(2,4-dimethyl 
pyridinium) -p ent-1 -ynyl] -b enZene dibromide 
Br % 
// Br 
@ % N\ / 
2Bre 
% N9 \ / 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (268 
mg, 0.73 mmol) and 2,4-lutidine (1 mL) Was heated at 60-700 
C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (15 mL), the aqueous solu 
tion Was extracted With diethyl ether (30 mL><3). Water Was 
removed by lyophiliZation to afford 343 mg of the title com 
pound.Yield: 81%. 1H NMR (300 MHZ, CD3OD) 6 2.34 (m, 
4H), 2.52 (s, 3H), 2.84 (t, 1:66 HZ, 4H), 2.97 (s, 3H), 4.87 (t, 
J:7.5 HZ, 4H), 7.27-7.45 (m, 4H), 7.80 (d, 1:63 HZ, 2H), 
7.87 (s, 2H), 8.99 (d, 1:63 HZ, 2H) ppm; l3CNMR (75 MHZ, 
CD3OD) 6 17.6, 20.9, 22.0, 30.1, 57.5, 81.6, 93.0, 126.4, 
127.6,129.1,131.7,133.0,145.5,155.5,160.3 ppm. 
Example 27 
Synthesis of Compound 1,2-bis-[5-(3,4-dimethyl 
pyridinium) -p ent-1 -ynyl] -b enZene dibromide 
Br 
// Br 
20 
25 
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-continued 
% N® 
% N@ 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (276 
mg, 0.75 mmol) and 3,4-lutidine (1 mL) Was heated at 60-700 
C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (15 mL), the aqueous solu 
tion Was extracted With diethyl ether (30 mL><3). Water Was 
removed by lyophiliZation to afford 355 mg of the title com 
pound. Yield: 81%. 1H NMR (300 MHZ, CD3OD) 6 2.37 (s, 
3H), 2.40 (s, 3H), 2.44 (m, 4H), 2.79 (t, 1:66 HZ, 4H), 4.88 
(t, 1:66 HZ, 4H), 7.29 (s, 4H), 7.86 (d, 1:63 HZ, 2H), 8.95 (d, 
1:63 HZ, 2H), 9.06 (s, 2H), ppm; 13C NMR (75 MHZ, 
CD3OD) 6 17.3, 17.7, 20.4, 31.1, 61.2, 81.3, 93.0, 126.5, 
129.0, 129.4, 132.8, 139.5, 142.7,144.3,159.8 ppm. 
Example 28 
Synthesis of Compound 1,2-bis-[5-(3,5-dimethyl 
pyridinium) -p ent-1 -ynyl] -b enZene dibromide 
Br 
// \\
Br 
1* / 
// \\
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (280 
mg, 0.76 mmol) and 3,5-lutidine (1 mL) Was heated at 60-700 
C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (15 mL), the aqueous solu 
tion Was extracted With diethyl ether (30 mL><3). Water Was 
removed by lyophiliZation to afford 363 mg of the title com 
pound. Yield: 82%. 1H NMR (300 MHZ, CD3OD) 6 2.42 (m, 
4H), 2.51 (s, 6H), 2.76 (t, 1:69 HZ, 4H), 4.86 (t, 1:69 HZ, 
4H), 7.30 (m, 4H), 8.13 (s, 2H), 8.95 (s,4H) ppm; 13C NMR 
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(75 MHZ, CD3OD) 6 17.7, 18.7, 31.2, 61.9, 81.6, 92.9, 126.6, 
129.0, 132.8, 140.2, 142.9, 147.9 ppm. 
Example 29 
Synthesis of Compound 
1 ,2-bis-(5 -quinolinium-pent-1-ynyl)-benZene 
dibromide 
% Br 
% Br 
% N? / 
2Bre 
% @— N\ / 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (249 
mg, 0.68 mmol) and quinoline (1 mL) Was heated at 60-700 C. 
for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (30 mL), the aqueous solu 
tion Was extracted With chloroform (20 mL><3). Water Was 
removed by lyophiliZation to afford 317 mg of the title com 
pound.Yield: 75 %. 1H NMR (300 MHZ, CD3OD) 6 2.42 (m, 
4H), 2.78 (t, 1:66 HZ, 4H), 5.36 (t, 1:69 HZ, 4H), 7.02-7.28 
(m, 4H), 7.97 (t, J :7.5 HZ, 2H), 8.07-8.40 (m, 4H), 8.67 (d, 
J:9.0 HZ, 2H), 9.15 (d, J:8.4 HZ, 2H), 9.15 (d, J:8.4 HZ, 2H), 
9.70 (d, J:5.7 HZ, 2H) ppm; 13C NMR (75 MHZ, CD3OD) 6 
178,298, 58.5, 81.6, 92.9, 119.7, 123.2, 126.2, 129.0, 130.5, 
131.3, 132.0, 132.7, 137.2, 139.0, 149.0, 150.6 ppm. 
Example 30 
Synthesis of Compound 
1,2-bis-(5 -isoquinolinium-pent-1-ynyl)-benZene 
dibromide 
% Br 
% Br 
01 
20 
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-continued 
% 
% 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (252 
mg, 0.68 mmol) and isoquinoline (1 mL) Was heated at 60-700 
C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (30 mL), the aqueous solu 
tion Was extracted With chloroform (20 mL><3). Water Was 
removed by lyophiliZation to afford 319 mg of the title com 
pound. Yield: 74%. 1H NMR (300 MHZ, CD3OD) 6 2.46 (m, 
4H), 2.77 (t, 1:63 HZ, 4H), 5.01 (t, 1:66 HZ, 4H), 6.91 (m, 
2H), 7.04 (m, 2H), 7.90-8.50 (m, 10H), 8.78 (d, 1:69 HZ, 
2H), 10.10 (s, 2H) ppm; l3CNMR (75 MHZ, CD3OD) 6 17.8, 
30.8, 62.1, 81.3, 92.7, 125.7, 127.3, 128.1, 128.5, 131.2, 
131.4,132.1,132.2,135.6,137.9,138.4,150.8 ppm. 
Example 31 
Synthesis of Compound 1,2-bis-[5-(2'-S-nicotinium 
pent- 1 -ynyl)]benZene dibromide 
% Br 
% Br 
,0. \ 
_ CH3 
% N? / 
21319 
% NJ 
\ / CH3 
/ 
N 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (330 
mg, 0.90 mmol) and S-nicotine (1 mL) Was heated at 60-700 
C. for 12 hrs. The resulted mixture Was Washed With diethyl 
ether and then dissolved in Water (20 mL), the aqueous solu 
tion Was extracted With chloroform (20 mL><3). Water Was 
removed by lyophiliZation to afford 340 mg of the title com 
pound.Yield: 55%. 1H NMR (300 MHZ, CD3OD) 6 2.00-2.82 
(m, 16H), 2.55 (s, 6H), 2.90 (m, 2H), 3.55 (m, 2H), 4.17 (m, 
2H), 4.95 (t, 1:69 HZ, 4H), 7.27 (m, 2H), 7.37 (m, 2H), 8.17 
(dd, J:7.8, 6.3 HZ, 2H), 8.69 (d, J:8.4 HZ, 2H), 9.15 (d, 1:60 

















































